These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19771930)

  • 1. Shiatsu as an adjuvant therapy for schizophrenia: an open-label pilot study.
    Lichtenberg P; Vass A; Ptaya H; Edelman S; Heresco-Levy U
    Altern Ther Health Med; 2009; 15(5):44-6. PubMed ID: 19771930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of electroconvulsive therapy in treatment-resistant schizophrenia: a prospective open trial.
    Tang WK; Ungvari GS
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):373-9. PubMed ID: 12691772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical response to clozapine treatment of 11 chronic patients in a state psychiatric hospital.
    Herman M
    Aust N Z J Ment Health Nurs; 1997 Sep; 6(3):129-33. PubMed ID: 9384012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of omega-3 fatty acids, vitamins E and C supplementation on treatment outcome and side effects in schizophrenia patients treated with haloperidol: an open-label pilot study.
    Sivrioglu EY; Kirli S; Sipahioglu D; Gursoy B; Sarandöl E
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1493-9. PubMed ID: 17688987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.
    Lerner V; Miodownik C; Gibel A; Kovalyonok E; Shleifer T; Goodman AB; Ritsner MS
    Clin Neuropharmacol; 2008; 31(1):25-33. PubMed ID: 18303488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flupenthixol treatment for cocaine abusers with schizophrenia: a pilot study.
    Levin FR; Evans SM; Coomaraswammy S; Collins ED; Regent N; Kleber HD
    Am J Drug Alcohol Abuse; 1998 Aug; 24(3):343-60. PubMed ID: 9741939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.
    Dolzan V; Serretti A; Mandelli L; Koprivsek J; Kastelic M; Plesnicar BK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1562-6. PubMed ID: 18573584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Generic quetiapine in the treatment of acute schizophrenia and schizoaffective disorder].
    György B; Robert K; László C; Andrea J;
    Neuropsychopharmacol Hung; 2008 Dec; 10(5):293-303. PubMed ID: 19419015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of quetiapine on cognitive functions in schizophrenia.
    Kivircik Akdede BB; Alptekin K; Kitiş A; Arkar H; Akvardar Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Feb; 29(2):233-8. PubMed ID: 15694229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of auricular acupressure as an adjuvant therapy in substance abuse treatment: a pilot study.
    Tian X; Krishnan S
    Altern Ther Health Med; 2006; 12(1):66-9. PubMed ID: 16454149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjunct extended-release valproate semisodium in late life schizophrenia.
    Sajatovic M; Coconcea N; Ignacio RV; Blow FC; Hays RW; Cassidy KA; Meyer WJ
    Int J Geriatr Psychiatry; 2008 Feb; 23(2):142-7. PubMed ID: 17582828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia.
    Lee KU; Jeon YW; Lee HK; Jun TY
    Hum Psychopharmacol; 2009 Aug; 24(6):447-52. PubMed ID: 19606454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility.
    Citrome L; Shope CB; Nolan KA; Czobor P; Volavka J
    Int Clin Psychopharmacol; 2007 Nov; 22(6):356-62. PubMed ID: 17917554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
    Delle Chiaie R; Salviati M; Fiorentini S; Biondi M
    Exp Clin Psychopharmacol; 2007 Dec; 15(6):563-8. PubMed ID: 18179309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy.
    Naeem F; Kingdon D; Turkington D
    Psychol Psychother; 2006 Jun; 79(Pt 2):153-64. PubMed ID: 16774715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study.
    Yamada K; Watanabe K; Nemoto N; Fujita H; Chikaraishi C; Yamauchi K; Yagi G; Asai M; Kanba S
    Psychiatry Res; 2006 Jan; 141(1):61-9. PubMed ID: 16318875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What impedes discharge support for persons with schizophrenia in psychiatric hospitals?].
    Ikebuchi E; Satoh S; Anzai N
    Seishin Shinkeigaku Zasshi; 2008; 110(11):1007-22. PubMed ID: 19202923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yi-gan san for the treatment of borderline personality disorder: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashia M; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):150-4. PubMed ID: 17765378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.